-
1.发明公开
公开(公告)号：EP4427744A1
公开(公告)日：2024-09-11
申请号：EP22889387.1
申请日：2022-11-03
发明人： GUO, Zhen , FU, Jun , NI, Hui , LU, Pengcheng , LIU, Yuli , WANG, Tingting , YING, Shuhuan
IPC分类号： A61K9/70 , A61K31/496 , A61P25/18
CPC分类号： A61K9/70 , A61P25/18 , A61K31/496
摘要： Provided are a lurasidone hydrochloride oral soluble film composition, a preparation method therefor and a use thereof. The lurasidone hydrochloride oral soluble film composition contains an active drug, a film-forming material, a plasticizer and a flavoring agent. The active drug is (3aR,4S,7R,7aS)-2-((1R,2R)-2-[4-(1.2-benzisothiazole 3-yl)piperazine-1-methyl]cyclohexylmethyl)hexahydro-4.7-methylene-2H-isoindole-1,3-dione hydrochloride, as shown in Formula I. The obtained lurasidone hydrochloride oral soluble film composition has a good dissolution rate, has no gravelly feeling in the oral cavity after dissolution, has a uniform appearance and good flexibility, and does not precipitate during the preparation of the film liquid; content uniformity thereof meets requirements.
-
公开(公告)号：EP4360622A1
公开(公告)日：2024-05-01
申请号：EP22827682.0
申请日：2022-06-24
发明人： CHEN, Zhixiang , CHEN, Bangyin , LIU, Shuang , GUO, Zhen , FU, Jun , WANG, Tingting , YING, Shuhuan
IPC分类号： A61K9/08 , A61K31/407 , A61K47/18 , A61P29/00
CPC分类号： A61P29/00 , A61K47/40 , A61K47/02 , A61K47/12 , A61K47/26 , A61K31/407 , A61K47/18 , A61K9/08
摘要： A ketorolac liquid composition, a preparation method therefor, and an application thereof. Provided is a ketorolac liquid composition, comprising the following components: ketorolac tromethamine, a stabilizer, a buffer, an osmotic pressure regulator, and a pH regulator; the ketorolac liquid composition does not contain ethanol; a concentration of ketorolac tromethamine is 0.15 mmol/L-160.00 mmol/L, and the concentration refers to a ratio of a molar amount of the ketorolac tromethamine to a volume of the ketorolac liquid composition. The ketorolac liquid composition does not contain an organic solvent, has stable physical and chemical properties, has less in-vivo irritation, has a lower adverse reactions, is safer and more convenient, can improve medication compliance of patients and the convenience of clinical administration, and has good market prospects.
-
3.发明公开
公开(公告)号：EP4378451A1
公开(公告)日：2024-06-05
申请号：EP22848634.6
申请日：2022-07-28
发明人： GUO, Zhen , WANG, Xuan , LU, Pengcheng , FU, Jun , WANG, Tingting , YING, Shuhuan
IPC分类号： A61K9/08 , A61K31/506 , A61P35/00
CPC分类号： A61K47/44 , A61K47/32 , A61K47/10 , A61K47/34 , A61K47/26 , A61P35/00 , A61K31/506 , A61K47/38 , A61K9/08
摘要： Provided are a pazopanib oral pharmaceutical composition, and a preparation method therefor and the use thereof. Provided is a pazopanib oral pharmaceutical composition, which comprises an active drug, a polymer carrier, an organic solvent and/or water, wherein the active drug is 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide as represented by formula I and a salt thereof. Dispersion of pazopanib in the form of a solution can significantly improve the solubility and dissolution rate of pazopanib, can significantly increase the drug bioavailability, and can also improve the compliance of a patient and solve the problems of dysphagia in elderly patients, etc.
-
4.发明公开
公开(公告)号：EP4371558A1
公开(公告)日：2024-05-22
申请号：EP22841360.5
申请日：2022-07-12
发明人： GUO, Zhen , XIE, Wenfeng , XIAO, Xiaoling , WANG, Tingting , YING, Shuhuan
CPC分类号： A61P9/04 , A61K9/209 , A61K9/50 , A61K31/216 , A61K9/20 , A61K47/32 , A61K47/10 , A61K47/02 , A61K47/12 , A61K9/28 , A61K9/2072 , A61K31/41 , A61K47/26 , A61K47/36 , A61K47/38
摘要： A sacubitril valsartan sodium sustained-release composition, and a preparation method therefor and the use thereof. The composition is a 24-hour sustained-release drug. Dissolution of sacubitril and valsartan simultaneously satisfies the following three features: A) dissolving no more than 40% of pharmaceutical active ingredients within 2 hours; B) dissolving 20%-75% of the pharmaceutical active ingredients within 8 hours; and C) dissolving not less than 65% of the pharmaceutical active ingredients within 24 hours. Compared with common gel sustained-release dosage forms, sacubitril and valsartan in the composition can achieve synchronous sustained release; moreover, the drug release behavior is not affected by factors such as the pH of a medium environment, gastrointestinal peristalsis, and foods, the in vivo and in vitro correlation is good, gentle release within 24 hours is achieved, and the therapeutic effect is good. Compared with common immediate-release formulations, the medication frequency is reduced, the patient compliance is improved, the medication compliance is improved for people having difficulty in swallowing such as the elderly and children, it is convenient to medicate, the toxic side effects are small, and the market prospects are good.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
